• 1
    Central Brain Tumor Registry of the United States (CBTRUS). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Hinsdale, Ill: CBTRUS; 2011. [accessed June 16, 2011].
  • 2
    Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997. J Neurosurg. 2003; 99: 458-466.
  • 3
    Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg. 1998; 88: 1-10.
  • 4
    Deorah S, Lynch CF, Sibenaller ZA, Ryken TC. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus. 2009; 20: E1.
  • 5
    Schering-Plough Corporation. First new chemotherapy agent for brain tumors in 20 years. [accessed March 14, 2011].
  • 6
    Mason WP, Cairncross JG. Drug insight: temozolomide as a treatment for malignant glioma--impact of a recent trial. Nat Clin Pract Neurol. 2005; 1: 88-95.
  • 7
    Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther. 2001; 1: 13-19.
  • 8
    Wiemels JL, Wilson D, Patil C, et al. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer. 2009; 125: 680-687.
  • 9
    Sher DJ, Henson JW, Avutu B, et al. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol. 2008; 88: 43-50.
  • 10
    Vinjamuri M, Adumala RR, Altaha R, Hobbs GR, Crowell EBJr. Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients. J Neurooncol. 2009; 91: 221-225.
  • 11
    Mutter N, Stupp R. Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther. 2006; 6: 1187-1204.
  • 12
    McKoy JM, Samaras A, Kaplan CE, Bennett CL. Temozolomide: applying healthcare fraud and abuse laws to oncology drugs. Community Oncol. 2008; 5: 553-554.
  • 13
    Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
  • 14
    Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005; 11: 6767-6771.
  • 15
    Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008; 64: 628-634.
  • 16
    Surveillance, Epidemiology and End Results. [accessed May 7, 2010].
  • 17
    Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology, 3rd ed. U.S. Interim Version 2000. Geneva: World Health Organization; 2000.
  • 18
    National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Number of persons by race and Hispanic ethnicity for SEER participants (2000 Census Data). [accessed March 24, 2011].
  • 19
    Davis FG, Malmer BS, Aldape K, et al. Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2008; 17: 484-489.
  • 20
    Chang SM, Barker FG 2nd. Marital status, treatment, and survival in patients with glioblastoma multiforme: a population based study. Cancer. 2005; 104: 1975-1984.
  • 21
    Wrensch M, Rice T, Miike R, et al. Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro-oncol. 2006; 8: 12-26.
  • 22
    Mrugala MM, Chamberlain MC. Mechanisms of disease: temozolomide and glioblastoma--look to the future. Nat Clin Pract Oncol. 2008; 5: 476-486.
  • 23
    Friedman HS. State-of-the-art therapy for glioblastoma multiforme. US Oncological Dis. 2007; 16-17.
  • 24
    Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009; 27: 5743-5750.
  • 25
    van Genugten JA, Leffers P, Baumert BG, Tjon-A-Fat H, Twijnstra A. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol. 2010; 96: 249-257.
  • 26
    Bauchet L, Mathieu-Daudé H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro-oncol. 2010; 12: 725-735.
  • 27
    Scoccianti S, Magrini SM, Ricardi U, et al. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neurosurg. 2010; 67: 446-458.
  • 28
    Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir. 2011; 153: 1211-1218.
  • 29
    Piepmeier JM. The future of neuro-oncology. Acta Neurochir. 2009; 151: 1343-1348.
  • 30
    Asthagiri AR, Pouratian N, Sherman J, Ahmed G, Shaffrey ME. Advances in brain tumor surgery. Neurol Clin. 2007; 25: 975-1003.
  • 31
    Sanai N, Berger MS. Operative techniques for gliomas and the value of extent of resection. Neurother. 2009; 6: 478-486.
  • 32
    Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, for the ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7: 392-401.
  • 33
    Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010; 16: 2443-2449.
  • 34
    Chamberlain MC. What role should cilengitide have in the treatment of glioblastoma? J Clin Oncol. 2010; 28: e695.
  • 35
    Narayana A, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys. 2006; 64: 892-897.
  • 36
    Scheithauer BW. Development of the WHO classification of tumors of the central nervous system: a historical perspective. Brain Pathol. 2009; 19: 551-564.
  • 37
    Siker ML, Wang M, Porter K, et al. Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison. J Neurooncol. 2011; 104: 351-356.
  • 38
    Barnholtz-Sloan JS, Williams VL, Maldonado JL, et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg. 2008; 108: 642-648.